Lp-PLA2: An emerging biomarker of coronary heart disease

Expert Review of Molecular Diagnostics

Volumn 2, Issue 1, 2002, Pages 17-22

  Dada, Nisha ^a   Kim, Nam W ^a   Wolfert, Robert L ^a  

^a diaDexus Inc   (United States)

Author keywords

Atherosclerosis coronary heart disease; Inflammation; Lipoprotein associated phospholipase A2, oxidized LDL

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A(2); LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2); LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A;

ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; ARTERIOSCLEROSIS; BLOOD; CHEMISTRY; CORONARY ARTERY DISEASE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; REGRESSION ANALYSIS;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEINS, LDL; PHOSPHOLIPASES A; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0035998298     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.1.17     Document Type: Review

References (42)

1. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study
2. Atherosclerosis - An inflammatory disease
3. Endothelium and acute coronary syndromes
4. The pathophysiology of acute coronary syndromes
5. The oxidative modification of atherosclerosis: An overview
6. The oxidation hypothesis of atherosclerosis
7. Atherosclerosis: The road ahead
8. Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein
9. Cell-mediated oxidation of LDL: Comparison of different cell types of the atherosclerotic lesion
10. Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma
11. Macrophages and atherosclerotic plaque stability
12. Purification, properties, sequencing and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins
13. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions
14. 2, platelet-activating factor acetylhydrolase: A potential new risk factor for coronary artery disease
15. HDL, its enzymes and its potential to influence lipid peroxidation
16. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions
17. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein
18. Circulating levels of secretory Type II phospholipase A(2) predict coronary events in patients with coronary artery disease
19. 2
20. 2 isoforms in human normal and atherosclerotic arterial wall
21. 2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins
22. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor
23. Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis
24. 2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages
25. Platelet-activating factor acetylhydrolases
26. 2: A potential new risk factor for coronary artery disease and a therapeutic target
27. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor
28. The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients
29. Plasma platelet-activating factor degradation in patients with severe coronary artery disease
30. Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease
31. Increased activity of the platelet activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension
32. Enhanced degradation of platelet-activating factor in serum from diabetic patients
33. Blood platelet behavior in patients with a Type I diabetes mellitus
34. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia
35. Variation in plasma platelet-activating factor degradation and serum lipids after myocardial infarction
36. Plasma platelet-activating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis
37. Platelet-activating factor acetylhydrolase deficiency: A missense mutation near the active site of an anti-inflammatory phospholipase
38. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age and atherosclerosis in a Japanese population
39. Plasma platelet activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan
40. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity
41. 2 as an independent predictor of coronary heart disease
42. 2 inhibition-a novel, nonlipid lowering strategy for atherosclerosis therapy